DNA-Guided CRISPR Flips Gene Editing Script, Opening a New Path for Precise Diagnosis and Antivirals

Why It Matters

Reversing CRISPR guidance delivers a more robust, scalable tool for rapid RNA diagnostics and potential antiviral treatments, eliminating cold‑chain constraints and improving precision. This could accelerate point‑of‑care testing and RNA‑targeted drug development worldwide.

Key Takeaways

• DNA guides Cas12a to cleave RNA, reversing traditional CRISPR logic
• SLEUTH platform detects SARS‑CoV‑2 at attomolar levels without cold chain
• DNA guides are cheaper and more stable than RNA guides for diagnostics
• HKUST filed US provisional patents, targeting antivirals and RNA‑based therapies

Pulse Analysis

The DNA‑guided CRISPR breakthrough flips the long‑standing paradigm that RNA serves as the address for Cas proteins. By engineering a synthetic DNA strand to act as the guide, HKUST researchers leveraged AlphaFold modeling, molecular dynamics, and cryo‑EM to confirm a functional deoxyribonucleoprotein capable of recognizing any RNA target. This structural innovation not only expands the CRISPR toolbox but also showcases how AI‑driven design can accelerate molecular engineering.

Beyond the science, the SLEUTH platform translates the discovery into a practical diagnostic solution. Coupled with isothermal amplification, it delivers attomolar sensitivity for SARS‑CoV‑2 and can operate without refrigeration, a critical advantage for low‑resource settings such as clinics, airports, and field stations. The use of DNA guides reduces synthesis costs and improves shelf‑life, while the Cas12a‑based system exhibits markedly lower off‑target cleavage than RNA‑targeting Cas13, enhancing safety for potential therapeutic applications.

Commercially, the technology positions HKUST at the forefront of next‑generation RNA diagnostics and antivirals. Two U.S. provisional patents have been filed, covering both the DNA‑guided enzyme and the SLEUTH workflow, paving the way for licensing or spin‑out ventures. Investors and biotech firms are likely to watch for partnerships that extend the platform to other respiratory pathogens, liquid‑biopsy cancer markers, and programmable RNA therapeutics, signaling a new revenue stream in the rapidly growing RNA‑based medicine market.